FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer By Ogkologos - July 4, 2025 23 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRUST-I and TRUST-II studies Source RELATED ARTICLESMORE FROM AUTHOR Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer EMA Recommends Extension of Indications for Cabozantinib MOST POPULAR FDA Approves Osimertinib for Locally Advanced, Unresectable Stage III Non-Small Cell... October 8, 2024 Building Your Fort of Support: Tips from a Breast Cancer Social... October 27, 2021 FDA Grants Regular Approval to fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic... May 9, 2022 Exercising Safely During Breast Cancer Treatment: What to Know October 27, 2022 Load more HOT NEWS How Does COVID-19 Affect People with Cancer? NCCAPS Will Help Find... Women in science: Cancer research pioneers – part 2 Inseparable Couples Dies 33 Hours Apart After 68 Years Of Marriage:... EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord
